Trexquant Investment’s Standard BioTools LAB Stock Holding History

Trexquant Investment’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-45,933	Closed	-$303K	–	1479
2021 Q3	$303K	Buy	45,933 +32,244	+236%	+$212K	0.02%	730
2021 Q2	$84K	Buy	+13,689	New	+$73.2K	0.01%	1029
2021 Q1	–	Sell	-51,680	Closed	-$310K	–	1299
2020 Q4	$310K	Buy	+51,680	New	+$340K	0.03%	668
2019 Q2	–	Sell	-48,538	Closed	-$645K	–	986
2019 Q1	$645K	Buy	48,538 +35,025	+259%	+$369K	0.05%	516
2018 Q4	$116K	Buy	+13,513	New	+$105K	0.01%	981
2018 Q3	–	Sell	-11,857	Closed	-$71K	–	1077
2018 Q2	$71K	Sell	11,857 -16,376	-58%	-$93.3K	﹤0.01%	849
2018 Q1	$165K	Buy	+28,233	New	+$185K	0.01%	972
2016 Q1	–	Sell	-23,400	Closed	-$253K	–	1053
2015 Q4	$253K	Sell	23,400 -41,085	-64%	-$403K	0.02%	891
2015 Q3	$522K	Buy	+64,485	New	+$1.01M	0.04%	709

Other funds holding LAB

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Trexquant Investment's LAB Position: Q4 2021 in Review

Trexquant Investment sold out of Standard BioTools (LAB) in Q4 2021, closing a stake of 45,933 shares — an estimated $303K sold.

Trexquant Investment first reported a position in LAB in Q3 2015 and held it in 9 quarters. The position peaked at $645K in Q1 2019. 121 funds tracked by Wall St. Rank hold LAB as of Q4 2021.

Trexquant Investment reported no remaining Standard BioTools position as of Q4 2021 after selling out during the quarter.
Trexquant Investment sold 45,933 Standard BioTools shares in Q4 2021, an estimated $303K.
Trexquant Investment first reported a position in Standard BioTools in Q3 2015 and held it in 9 quarters.
Trexquant Investment's Standard BioTools position peaked at $645K in Q1 2019.
121 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2021.

Based on Trexquant Investment's 13F filing for Q4 2021, filed 14 Feb 2022.